TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33386826

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy combined with cycling exercise (cycle ergometer session for five consecutive days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional physiotherapy (twice a day)
Number of subjects: 20
Study: 32151044

Group type: EXPERIMENTAL
Intervention: Standing meetings
Number of subjects: 173

Group type: COMPARATOR
Intervention: Walking meetings
Number of subjects: 173
Study: 35394895

Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture (AA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Auricular Acupuncture (AA without needle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 0
Study: 34181580

Group type: EXPERIMENTAL
Intervention: Rg1 (5 mg) supplementation 1 hour before squat exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Squat exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rg1 (5 mg) supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 33508141

Group type: EXPERIMENTAL
Intervention: Alexandrite laser alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nd YAG laser alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Blended 755/1064 nm laser
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 70/30 mixture of Nd:YAG and alexandrite
Number of subjects: 36
Study: 32353001

Group type: EXPERIMENTAL
Intervention: Clinical laboratory services satisfaction
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Existing laboratory request form
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Legibility and completeness of laboratory report
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Notification of new test
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Test interruption
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Absence of laboratory hand book
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Existing test menu
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Lab-physician interface
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Availability of referral and/or back up service
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Notification of Turn Around Time (TAT)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Timely notification of panic result
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Long Turn Around Time (TAT)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Provision of urgent service
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Timely advisory service
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Consistent quality of service delivery
Number of subjects: 327
Study: 35550371

Group type: EXPERIMENTAL
Intervention: Standard opioid prescription (ten 5-mg oxycodone tablets provided preoperatively)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Restricted opioid prescription (provided only during patient request postoperatively)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (using opioids)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Standard arm
Number of subjects: 82

Group type: COMPARATOR
Intervention: Restricted arm
Number of subjects: 82
Study: 34325831

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 32652462

Group type: EXPERIMENTAL
Intervention: Weekly SMS reminder
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 244
Study: 35382842

Group type: EXPERIMENTAL
Intervention: TAK228 plus weekly paclitaxel
Number of subjects: 124

Group type: COMPARATOR
Intervention: Weekly paclitaxel alone (standard treatment)
Number of subjects: 124
Study: 33863242

Group type: EXPERIMENTAL
Intervention: Expert Recommendations for Implementing Change strategies
Number of subjects: 0
Study: 32560503

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet Therapy (KDT) including classic ketogenic diet (cKD), modified Atkins diet (MAD), medium chain triglyceride ketogenic diet (MCTKD), low glycemic index treatment (LGIT)
Number of subjects: 0
Study: 34028038

Group type: EXPERIMENTAL
Intervention: Affective learning method
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 32518064

Group type: EXPERIMENTAL
Intervention: SU (glimepiride 1 mg) + GIP (1.5 pmol/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SU (glimepiride 1 mg) + GLP-1 (0.5 pmol/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo + saline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SU (glimepiride 1 mg) + placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 20
Study: 35955129

Group type: EXPERIMENTAL
Intervention: Eccentric hamstring training (6 weeks, twice weekly) in post-PHV group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Eccentric hamstring training (6 weeks, twice weekly) in pre-PHV group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (pre-PHV)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (post-PHV)
Number of subjects: 45
Study: 34531424

Group type: EXPERIMENTAL
Intervention: Intensified physiotherapy (n=22)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard physiotherapy (n=25)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 35664039

Group type: EXPERIMENTAL
Intervention: Polyp-based strategy
Number of subjects: 944

Group type: COMPARATOR
Intervention: Optical diagnosis for small polyps (< 10 mm)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Optical diagnosis
Number of subjects: 944
Study: 33307906

Group type: EXPERIMENTAL
Intervention: Luteal phase support (LPS) with vaginal progesterone
Number of subjects: 59

Group type: COMPARATOR
Intervention: No luteal phase support (No-LPS)
Number of subjects: 59
Study: 34583626

Group type: EXPERIMENTAL
Intervention: Regulation Focused Psychotherapy for Children (RFP-C)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 43
Study: 34631028

Group type: EXPERIMENTAL
Intervention: Personalised text message (early)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Personalised text message (late)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Non-personalised text message (early)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Non-personalised text message (late)
Number of subjects: 194
Study: 33049804

Group type: EXPERIMENTAL
Intervention: SPN-812 (1,800 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32279063

Group type: EXPERIMENTAL
Intervention: Targeted smartphone application (TSPA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-programmable calculator (NPC)
Number of subjects: 48
Study: 33006755

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 99
Study: 32515065

Group type: EXPERIMENTAL
Intervention: Pre-fatigue of the diaphragm (PTL) prior to exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: No PTL (control)
Number of subjects: 16
Study: 36374508

Group type: EXPERIMENTAL
Intervention: ICM monitoring
Number of subjects: 496

Group type: COMPARATOR
Intervention: Site-specific usual care (short-duration external cardiac monitoring)
Number of subjects: 496
Study: 34000112

Group type: EXPERIMENTAL
Intervention: Pharmacist Comprehensive Medication Management Services (PCS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Modified or No CMM Services (NCS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pharmacist Comprehensive Medication Management Services (PCS) and Modified or No CMM Services (NCS)
Number of subjects: 120
Study: 32925435

Group type: EXPERIMENTAL
Intervention: IVRA with 300 mg lidocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Axillary block with 280 mg mepivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IVRA
Number of subjects: 120

Group type: COMPARATOR
Intervention: Axillary block
Number of subjects: 120
Study: 34391588

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 539
Study: 33258422

Group type: EXPERIMENTAL
Intervention: ENABLE CHF-PC intervention
Number of subjects: 415
Study: 33320964

Group type: EXPERIMENTAL
Intervention: COSIMO model-derived screening for colorectal cancer
Number of subjects: 0
Study: 35641112

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 188
Study: 33675672

Group type: EXPERIMENTAL
Intervention: Mirror therapy along with a Stroke rehabilitation program
Number of subjects: 38

Group type: COMPARATOR
Intervention: Stroke rehabilitation program without mirror therapy
Number of subjects: 38
Study: 32221086

Group type: EXPERIMENTAL
Intervention: Self-adhesive breast prostheses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional breast prostheses
Number of subjects: 30
Study: 35286136

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus standard chemotherapy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard chemotherapy alone
Number of subjects: 1000
Study: 33967022

Group type: EXPERIMENTAL
Intervention: Age group 20–64 years
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Age group 65–84 years
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Age group 85+ years
Number of subjects: 230
Study: 32794334

Group type: EXPERIMENTAL
Intervention: MRI-determined maximal axial diameter (MAD) of cervical lymph nodes = 4 cm in the training group (n = 1033)
Number of subjects: 2066

Group type: EXPERIMENTAL
Intervention: MAD = 4 cm classified as N3 in the N classification
Number of subjects: 2066

Group type: EXPERIMENTAL
Intervention: Proposed N staging system
Number of subjects: 2066
Study: 35696601

Group type: EXPERIMENTAL
Intervention: Local Vibration Therapy (VT) for 10 minutes at 45 Hz, starting 1 hour post-exercise, applied twice daily for 48 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no local VT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Local Vibration Therapy (VT)
Number of subjects: 10
Study: 33522961

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 99

Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 99
Study: 34250916

Group type: EXPERIMENTAL
Intervention: tDCS + VR
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS + VR
Number of subjects: 20
Study: 33510503

Group type: EXPERIMENTAL
Intervention: Substandard medicines found in health facilities
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Labeling and storage conditions of medicines
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Storage requirements compliance
Number of subjects: 88
Study: 34621011

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day plus androgen deprivation therapy (ADT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Bicalutamide 50 mg/day plus ADT
Number of subjects: 139
Study: 33556352

Group type: EXPERIMENTAL
Intervention: Yoga classes
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) sessions
Number of subjects: 320

Group type: COMPARATOR
Intervention: Education (control group)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: All treatments (yoga, PT, education)
Number of subjects: 320
Study: 36198143

Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitoring
Number of subjects: 156

Group type: COMPARATOR
Intervention: Fingerstick testing (usual-care group)
Number of subjects: 156
Study: 33538520

Group type: EXPERIMENTAL
Intervention: Collagen signature in the tumor microenvironment
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Collagen signature based on 3 features
Number of subjects: 416

Group type: COMPARATOR
Intervention: Clinicopathological model (4 risk factors: obstruction or perforation, lymphovascular invasion, tumor budding, no chemotherapy)
Number of subjects: 416
Study: 32139135

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg kg‐1
Number of subjects: 200

Group type: COMPARATOR
Intervention: Neostigmine 0.07 mg kg‐1 (maximum 5 mg)
Number of subjects: 200
Study: 34716106

Group type: EXPERIMENTAL
Intervention: Honey gargling every six hours for ten days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo gargling every six hours for ten days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard post-operative regimens
Number of subjects: 24
Study: 34411252

Group type: EXPERIMENTAL
Intervention: Baseline opioid use
Number of subjects: 241
Study: 32964675

Group type: EXPERIMENTAL
Intervention: Genetically predicted BMI
Number of subjects: 850000

Group type: EXPERIMENTAL
Intervention: Genetically predicted WHR
Number of subjects: 850000

Group type: EXPERIMENTAL
Intervention: Genetically predicted WHRadjBMI
Number of subjects: 850000
Study: 33593781

Group type: EXPERIMENTAL
Intervention: Continuous landiolol infusion to reduce heart rate between 80 and 94 bpm
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual care (according to international standards)
Number of subjects: 340
Study: 33305993

Group type: EXPERIMENTAL
Intervention: Oral oncolytic agents (OAs)
Number of subjects: 230
Study: 35842975

Group type: EXPERIMENTAL
Intervention: CRASH score (derived from 312,393 patients in the derivation set)
Number of subjects: 624786

Group type: EXPERIMENTAL
Intervention: CRASH score validation
Number of subjects: 624786
Study: 33719448

Group type: EXPERIMENTAL
Intervention: Non-fat dairy milk
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Full-fat dairy milk
Number of subjects: 7

Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 7
Study: 34598146

Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy plus choroid plexus cauterization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subdural collections presence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayley-III cognitive score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative CSF volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Causal mediation analysis
Number of subjects: 0
Study: 34487441

Group type: EXPERIMENTAL
Intervention: Basal insulin plus GLP-1 RA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal insulin plus SGLT2 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal-bolus insulin intensification
Number of subjects: 0
Study: 35568679

Group type: EXPERIMENTAL
Intervention: Metformin in COU-AA-301-AAP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin in COU-AA-302-AAP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin in COU-AA-302-P
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin pooled analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins in COU-AA-301-AAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins in COU-AA-301-P
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins in COU-AA-302 groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins pooled analysis
Number of subjects: 0
Study: 33745697

Group type: EXPERIMENTAL
Intervention: Cognitive Task Analysis (CTA) learning tool
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard operative technique manual for antegrade femoral intramedullary nailing (Control)
Number of subjects: 14
Study: 35951432

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (one piece for 15 minutes, 3 times daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard postoperative care (control group)
Number of subjects: 60
Study: 33443117

Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg evening dose (qd)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg morning dose and 15 mg evening dose (bid)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo morning dose and evening dose
Number of subjects: 88
Study: 32870155

Group type: EXPERIMENTAL
Intervention: Propofol medium-chain triglyceride (MCT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol long-chain triglyceride (LCT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both propofol MCT and LCT preparations
Number of subjects: 30
Study: 35812088

Group type: EXPERIMENTAL
Intervention: Nabiximols oromucosal spray
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 35403393

Group type: EXPERIMENTAL
Intervention: Fang's scalp acupuncture combined with conventional acupuncture
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 66
Study: 34115329

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor (Asian sub-population outcomes)
Number of subjects: 0
Study: 33430665

Group type: EXPERIMENTAL
Intervention: Amlodipine (Calcium Channel Blocker)
Number of subjects: 210
Study: 34170188

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 570

Group type: COMPARATOR
Intervention: Buprenorphine-naloxone
Number of subjects: 570
Study: 34578782

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: VDR gene polymorphism (rs11568820 and rs4516035)
Number of subjects: 142
Study: 33248625

Group type: EXPERIMENTAL
Intervention: Low-calcium diet (1.5%)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control calcium diet
Number of subjects: 72
Study: 36250317

Group type: EXPERIMENTAL
Intervention: VAC (vincristine-dactinomycin-cyclophosphamide)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: VAI (vincristine-dactinomycin-ifosfamide)
Number of subjects: 172

Group type: COMPARATOR
Intervention: VAC
Number of subjects: 172

Group type: COMPARATOR
Intervention: VAI
Number of subjects: 172
Study: 33597580

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg doses administered via chewing gum, four doses during night-time)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 32305930

Group type: EXPERIMENTAL
Intervention: MusicGlove (wearable grip sensor integrated with a musical computer game)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MusicGlove
Number of subjects: 11
Study: 35192908

Group type: EXPERIMENTAL
Intervention: iBond® Universal in self‐etch mode (iBU‐SE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iBond® Universal in selective‐enamel-etch mode (iBU‐SEE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iBond® Universal in etch‐and‐rinse mode (iBU‐ER)
Number of subjects: 50

Group type: COMPARATOR
Intervention: OptiBond™ FL (OFL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All groups (iBU and OFL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iBU‐SE vs. iBU‐SEE
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iBU‐ER vs. iBU‐SE
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iBU‐ER vs. OFL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iBU vs. OFL at dentin/cement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iBU‐SE vs. iBU‐ER
Number of subjects: 50
Study: 33822798

Group type: EXPERIMENTAL
Intervention: Moringa oleifera capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35570039

Group type: EXPERIMENTAL
Intervention: 7% iodine tincture umbilical dip (n = 140)
Number of subjects: 284

Group type: COMPARATOR
Intervention: No treatment (control group, n = 144)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: 7% iodine tincture umbilical dip
Number of subjects: 284
Study: 33761901

Group type: EXPERIMENTAL
Intervention: US-guided bilateral posterior TAPB with RSB (40 mL 0.33% ropivacaine + 20 mL 0.33% ropivacaine)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: US-guided bilateral posterior TAPB alone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Saline alone (Control Group)
Number of subjects: 78
Study: 35292085

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) applied for varying times (3, 5, 10, 15, 30, 45, 60, 120, and 180 seconds)
Number of subjects: 414

Group type: COMPARATOR
Intervention: 38% silver diamine fluoride (SDF)
Number of subjects: 414
Study: 33875729

Group type: EXPERIMENTAL
Intervention: cathodal tDCS during aerobic exercise
Number of subjects: 122

Group type: COMPARATOR
Intervention: cathodal tDCS alone
Number of subjects: 122

Group type: COMPARATOR
Intervention: anodal tDCS during aerobic exercise
Number of subjects: 122

Group type: COMPARATOR
Intervention: anodal tDCS alone
Number of subjects: 122

Group type: COMPARATOR
Intervention: aerobic exercise
Number of subjects: 122

Group type: COMPARATOR
Intervention: active control during aerobic exercise
Number of subjects: 122
Study: 35982258

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34781915

Group type: EXPERIMENTAL
Intervention: Training group (n=508)
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: Validation group (n=507)
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: Model developed using six variables
Number of subjects: 1079
Study: 32604406

Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg plus oseltamivir 75 mg twice daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus oseltamivir 75 mg twice daily for 7 days
Number of subjects: 0
Study: 33662625

Group type: EXPERIMENTAL
Intervention: High-confidence SV calls established using multiple technologies (109× PacBio CLR, 22× PacBio CCS, 104× Oxford Nanopore long reads, 114× optical mapping platform, and one de novo assembly-based SV caller using CCS reads)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trio-binning based haplotype assemblies
Number of subjects: 0
Study: 32678716

Group type: EXPERIMENTAL
Intervention: Neratinib (240 mg once daily) plus capecitabine (750 mg/m2 twice daily for 14 days of a 21-day cycle)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Lapatinib (1,250 mg once daily) plus capecitabine (1,000 mg/m2 twice daily for 14 days of a 21-day cycle)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Neratinib plus capecitabine
Number of subjects: 621

Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine
Number of subjects: 621